DiagnaMed Holdings Corp. (TSE:DMED) has released an update.
DiagnaMed Holdings Corp. is leveraging its BRAIN AGE Brain Health AI Platform to study the effects of weight loss drugs, like Semaglutide, on brain function. The platform aims to identify potential brain health issues and provide insights into cognitive performance during treatment. This could lead to personalized approaches for maintaining or enhancing brain health amid the rising global market for obesity drugs.
For further insights into TSE:DMED stock, check out TipRanks’ Stock Analysis page.
